Abstract
Objective: To evaluate the role of topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN). Design: Noncomparative case series. Participants: Five patients with histologically proven CIN or recurrences of proven CIN were studied prospectively. Intervention: After histologic confirmation, patients were given topical recombinant IFNα2b (INTRON A, Schering Plough, Kenilworth, NJ) 1 million IU/ml four times a day. Patients were continued on interferon until complete resolution of the tumor had occurred. Main Outcome Measures: Patients were followed clinically and photographically for evidence of tumor resolution. Results: All patients had complete resolution of the CIN lesion on IFNα2b. The mean time to clinical resolution was 11.6 weeks (range, 4-22 weeks). The mean follow-up was 17.6 months (range, 7-28 months). One patient had a clinical recurrence of his corneal CIN 1 year after tumor resolution. This patient was retreated, resulting in clinical resolution within 6 weeks, and has been tumor free for 8 months of follow-up.
Original language | English (US) |
---|---|
Pages (from-to) | 1093-1098 |
Number of pages | 6 |
Journal | Ophthalmology |
Volume | 108 |
Issue number | 6 |
DOIs | |
State | Published - Jun 13 2001 |
ASJC Scopus subject areas
- Ophthalmology